CCS-1477 (CBP-IN-1)
规格
| Cas Number | 2222941-37-7 |
| 规格或纯度 | ≥98% |
| 纯度 | ≥98% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (187.05 mM); Ethanol: 100 mg/mL (187.05 mM); Water: Insoluble; |
| 简短描述 | Myc 抑制剂 |
| 英文简短描述 | Myc Inhibitors |
| 过滤标签 | 表观遗传学,Epigenetic Reader Domain |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | CCS1477（CBP-IN-1, CBP/p300-IN-4）是一种有效的p300/CBP溴链选择性抑制剂。CCS1477通过抑制雄激素受体（AR）的表达和功能以及抑制c-Myc而发挥作用。 |
| 描述 |
Inobrodib (CCS1477; CBP-IN-1; CBP/p300-IN-4）是一种有效的和选择性的 p300/CBP bromodomain 的抑制剂。CCS1477 通过抑制 androgen receptor (AR) 的表达和功能以及抑制 c-Myc 起作用。 |
| 英文描述 |
Information CCS-1477 (CBP-IN-1) CCS1477（CBP-IN-1, CBP/p300-IN-4）is a potent and selective inhibitor of p300/CBP bromodomain . CCS1477 works by inhibiting the expression and function of the androgen receptor (AR) , as well as inhibiting c-Myc . Targets p300/CBP bromodomain ; androgen receptor ; c-Myc In vitro CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and C-MYC–regulated gene expression. In vivo In AR-SV–driven models, CCS1477 has antitumor activity, regulating AR and C-MYC signaling. Early clinical studies suggest that CCS1477 modulates KLK3 blood levels and regulates CRPC biopsy biomarker expression. Cell Research(from reference) Cell lines：22Rv1 cells, C4-2 cells Concentrations：500 nM, 96 nM Incubation Time：5 hr, 24 hr |